Half-year report · Q2
4893.TEDINET S100WI8E
Period2025-01-01 → 2025-06-30
Filed2025-08-08
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Operating income | −¥413m | 2025-01-01 → 2025-06-30 | Standalone | Operating income |
| Operating income | −¥682m | 2024-01-01 → 2024-06-30 | Standalone | Operating income |
| Ordinary income | −¥410m | 2025-01-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥962m | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥682m | 2024-01-01 → 2024-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥410m | 2025-01-01 → 2025-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥682m | 2024-01-01 → 2024-06-30 | Standalone | Income before income taxes |
| Net income | −¥412m | 2025-01-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | −¥964m | 2024-01-01 → 2024-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥683m | 2024-01-01 → 2024-06-30 | Standalone | Profit loss |
| Total assets | ¥4.4bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥4.8bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥5.1bn | at 2024-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥68m | at 2025-06-30 | Standalone | Liabilities |
| Total liabilities | ¥75m | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥4.3bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥4.7bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥5.0bn | at 2024-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.3bn | at 2025-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥4.3bn | at 2025-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2024-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥5.6bn | at 2023-12-31v | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥357m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥888m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥611m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | ¥0 | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥557,000 | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥557,000 | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | −¥20,000 | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥3m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-9.51 | 2025-01-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-22.28 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-15.79 | 2024-01-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 98.3% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.3% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.3% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 43,301,765 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,301,765 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,301,765 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 357
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes segment information etc quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment | CurrentYTDDuration_NonConsolidatedMember | Original text (Japanese)当社は、がん免疫療法創薬事業の単一セグメントであり、セグメント情報の記載を省略しております。 | |
| Notes revenue recognition quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |